Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01435993 (ClinicalTrials.gov)	September 8, 2011	25/8/2011	Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis	A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK1223249;Other: Saline placebo	GlaxoSmithKline	NULL	Terminated	18 Years	60 Years	All	3	Phase 1	Italy;Norway;Germany
2	NCT01424423 (ClinicalTrials.gov)	February 11, 2010	9/6/2011	NOGO-A in Multiple Sclerosis FTIH	A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy	Multiple Sclerosis	Drug: Placebo;Drug: GSK1223249	GlaxoSmithKline	NULL	Terminated	18 Years	55 Years	All	3	Phase 1	Australia